Gene info: ID 4130

Gene: MAP1A

GENE ID: 4130

Synonyms: MAP1L|MTAP1A

Description: microtubule associated protein 1A

Gene type: protein-coding

Location: 15q15.3

dbXrefs: Ensembl:ENSG00000166963 MIM:600178 Vega:OTTHUMG00000059756 UniprotKB:P78559

RefSeq: NC_000015.10

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 1

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 4.515e-1 (AD) 7.862e-1 (ND)

DNA Methylation

Probe	Locus(GRCh37)	Gene	Region	p-val	Trait	PubMed ID
cg22377043	chr15:43809486	MAP1A		3.000e-10	Smoking	27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
EPB41L1	0.968
PIP4K2B	0.95
ATP6V0A1	0.949
RNF157	0.945
SPTAN1	0.944
MAPT	0.944
SCAMP5	0.944
RUSC2	0.944
CAMTA2	0.944
FAIM2	0.94

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.632
OR4F29	-0.631
TFPI2	-0.505
C9orf135	-0.47
WWTR1	-0.432
CCR2	-0.429
ARHGEF5	-0.429
C1orf87	-0.429
IL18RAP	-0.427
ZNF114	-0.425

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB01196	Estramustine	Small Molecule	2998-57-4	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C011269	2,5-hexanedione	"2,5-hexanedione results in decreased expression of MAP1A protein"	20554699
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in increased expression of MAP1A mRNA	29067470
D000082	Acetaminophen	Acetaminophen affects the expression of MAP1A mRNA	17562736
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of MAP1A gene	27153756
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of MAP1A mRNA	16483693
D001280	Atrazine	Atrazine results in increased expression of MAP1A mRNA	22378314
D001374	Azacitidine	Azacitidine results in decreased expression of MAP1A mRNA	20823114
C547126	AZM551248	AZM551248 results in increased expression of MAP1A mRNA	22323515
C006703	benzo(b)fluoranthene	benzo(b)fluoranthene results in increased expression of MAP1A mRNA	26377693
D004958	Estradiol	[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA	20823114
C543008	bis(4-hydroxyphenyl)sulfone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of MAP1A mRNA	28628672
C006780	bisphenol A	bisphenol A results in increased expression of MAP1A mRNA	25594700
C006780	bisphenol A	bisphenol A affects the expression of MAP1A mRNA	25181051
D020245	p-Chloromercuribenzoic Acid	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA"	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in increased expression of MAP1A mRNA	26272509
D003024	Clozapine	Clozapine results in increased expression of MAP1A mRNA	15860345
D003042	Cocaine	Cocaine results in increased expression of MAP1A mRNA	16076954
D019327	Copper Sulfate	Copper Sulfate results in increased expression of MAP1A mRNA	19549813
D003907	Dexamethasone	Dexamethasone results in increased expression of MAP1A mRNA	12782123
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of MAP1A mRNA	28628672
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of MAP1A mRNA	21266533
D003994	Bucladesine	[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA	20823114
D004041	Dietary Fats	Dietary Fats results in increased expression of MAP1A mRNA	25016146
D019813	1,2-Dimethylhydrazine	"[APC protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in decreased expression of MAP1A mRNA"	27840820
D004610	Ellagic Acid	Ellagic Acid results in decreased expression of MAP1A mRNA	12002526
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of MAP1A mRNA	17912697
D006220	Haloperidol	Haloperidol results in increased expression of MAP1A mRNA	15860345
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of MAP1A protein	21179406
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of MAP1A mRNA	28628672
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of MAP1A mRNA	28628672
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in increased expression of MAP1A mRNA	24796395\|2675264
D007657	Ketone Bodies	Ketone Bodies results in increased expression of MAP1A mRNA	16807920
D007854	Lead	Lead results in decreased expression of MAP1A mRNA	19921347
D017258	Medroxyprogesterone Acetate	[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA	20823114
C042720	mercuric bromide	mercuric bromide results in increased expression of MAP1A mRNA	26272509
C042720	mercuric bromide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA"	27188386
D008694	Methamphetamine	Methamphetamine results in increased expression of MAP1A protein	19826936
C406082	monomethylarsonous acid	monomethylarsonous acid results in increased expression of MAP1A protein	24625837
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAP1A mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of MAP1A mRNA	26272509
C006253	pirinixic acid	pirinixic acid results in increased expression of MAP1A mRNA	20813756
D011192	Potassium Dichromate	Potassium Dichromate results in decreased expression of MAP1A mRNA	23608068
D011374	Progesterone	Progesterone results in decreased expression of MAP1A mRNA	23012394
D011374	Progesterone	Progesterone results in decreased expression of MAP1A mRNA	19690047
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of MAP1A mRNA	24780913
C009131	pyrimidin-2-one beta-ribofuranoside	pyrimidin-2-one beta-ribofuranoside results in increased expression of MAP1A mRNA	19194470
D011929	Razoxane	Razoxane results in decreased expression of MAP1A mRNA	19915844
C059514	resveratrol	resveratrol results in decreased expression of MAP1A mRNA	12569576
D013629	Tamoxifen	Tamoxifen results in increased expression of MAP1A mRNA	15590111
C012589	trichostatin A	trichostatin A affects the expression of MAP1A mRNA	28542535
D014520	Urethane	Urethane results in increased expression of MAP1A mRNA	28818685
D014635	Valproic Acid	Valproic Acid affects the expression of MAP1A mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of MAP1A mRNA	23179753
D014635	Valproic Acid	Valproic Acid results in increased expression of MAP1A mRNA	23665938
D001335	Vehicle Emissions	Vehicle Emissions analog results in increased expression of MAP1A mRNA	15541757

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0003779	actin binding	-	IBA	21873635
GO:0003779	actin binding	-	ISS	-
GO:0005198	structural molecule activity	-	NAS	8812494
GO:0005515	protein binding	-	IPI	12812986 15251455 15525354
GO:0008017	microtubule binding	-	IBA	21873635
GO:0008017	microtubule binding	-	ISS	-
GO:0008017	microtubule binding	-	TAS	26609151
GO:0008093	cytoskeletal adaptor activity	-	ISS	-
GO:0015631	tubulin binding	-	IBA	21873635
GO:0015631	tubulin binding	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000226	microtubule cytoskeleton organization	-	IBA	21873635
GO:0000226	microtubule cytoskeleton organization	-	ISS	-
GO:0007409	axonogenesis	-	IBA	21873635
GO:0007613	memory	-	ISS	-
GO:0008306	associative learning	-	ISS	-
GO:0016358	dendrite development	-	IBA	21873635
GO:0031114	regulation of microtubule depolymerization	-	IBA	21873635
GO:0032435	negative regulation of proteasomal ubiquitin-dependent protein catabolic process	-	ISS	-
GO:0048167	regulation of synaptic plasticity	-	ISS	-
GO:0050882	voluntary musculoskeletal movement	-	ISS	-
GO:0070050	neuron cellular homeostasis	-	ISS	-
GO:0099641	anterograde axonal protein transport	-	ISS	-
GO:0099642	retrograde axonal protein transport	-	ISS	-
GO:1902817	negative regulation of protein localization to microtubule	-	ISS	-
GO:1903829	positive regulation of cellular protein localization	-	ISS	-
GO:1990535	neuron projection maintenance	-	ISS	-
GO:2000010	positive regulation of protein localization to cell surface	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005737	cytoplasm	-	ISS	-
GO:0005829	cytosol	-	IBA	21873635
GO:0005874	microtubule	-	IBA	21873635
GO:0005875	microtubule associated complex	-	IBA	21873635
GO:0005875	microtubule associated complex	-	TAS	8812494
GO:0030424	axon	-	ISS	-
GO:0030425	dendrite	-	IBA	21873635
GO:0030425	dendrite	-	ISS	-
GO:0042995	cell projection	-	IBA	21873635
GO:0043005	neuron projection	-	ISS	-
GO:0043025	neuronal cell body	-	IBA	21873635
GO:0043025	neuronal cell body	-	ISS	-
GO:0043194	axon initial segment	-	ISS	-
GO:0043198	dendritic shaft	-	ISS	-
GO:0044307	dendritic branch	-	ISS	-
GO:0045202	synapse	-	IBA	21873635
GO:0150001	primary dendrite	-	ISS	-
GO:1901588	dendritic microtubule	-	ISS	-
GO:1904115	axon cytoplasm	-	IEA	-

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
29762635	An Epigenome-Wide Association Study (EWAS) of Obesity-Related Traits. (2018 May 14)	Dhana K	Am J Epidemiol